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S urvival from most cancers has improved, but interna-tional variations persist, with poorer survival in theUnitedKingdomthanotherdeveloped countries. Varia-
tions in outcomes manifest soon after diagnosis. For ex-
ample, socioeconomic variations in survival from colorectal
cancers are largely confined to excess mortality in the post-
operative period, and international variations in breast can-
cer survival aremost pronounced in the first month and year
after diagnosis.1,2 However, it remains unclear what medi-
atesbetter survival. Ithasbeensuggested thatqualityofhealth
caremayexplain international variations in canceroutcomes.3
While this is often considered in terms of availability and ef-
fectiveness of therapeutic interventions, the role of support-
ive care to prevent or ameliorate critical illness among pa-
tients with cancer may also be important.
The development of a critical illness requiring support in
an intensive care unit (ICU) has received relatively little
attention for patients with cancer. ICUs provide enhanced
physiological monitoring and support of organ system fail-
ure, with higher than normal staff-to-patient ratios and
greater costs.4 ICU care is physically and psychologically
traumatic and is associated with persisting morbidity after
discharge.5,6 The United Kingdom has considerably lower
provision of ICU beds, at 3.5 per 100 000 population, than
other European countries, North America, and Australasia.7
Among the EUROCARE countries, those with consistently
IMPORTANCE Critical illness may be a potential determinant of cancer outcomes and
geographic variations, but its role has not been described before.
OBJECTIVE To determine the incidence of admission to intensive care units (ICUs) within 2
years following cancer diagnosis.
DESIGN, SETTING, AND PARTICIPANTS This was a retrospective observational study using
cancer registry data in 4 datasets from 2000 to 2009with linked ICU admission data from
2000 to 2011, in theWest of Scotland region of the United Kingdom (population, 2.4 million;
all 16 ICUs within the region). All 118 541 patients (16 years) diagnosed as having solid
(nonhematological) cancers. Their median age was 69 years, and 52.0%were women.
MAIN OUTCOMES ANDMEASURES Demographic and clinical variables associatedwith
admission to an ICU and death in an ICU.
RESULTS A total of 118 541 patients met the study criteria. Overall, 6116 patients (5.2% [95%
CI, 5.0%-5.3%]) developed a critical illness and were admitted to an ICUwithin 2 years. Risk
of critical illness was highest at ages 60 to 69 years and higher in men. The cumulative
incidence of critical illness was greatest for small intestinal (17.2% [95% CI, 13.3%-21.8%]) and
colorectal cancers (16.5% [95% CI, 15.9%-17.1%]). The risk following breast cancer was low
(0.8% [95% CI, 0.7%-1.0%]). The percentage who died in ICUs was 14.1% (95% CI,
13.3%-15.0%), and during the hospital stay, 24.6% (95% CI, 23.5%-25.7%). Mortality was
greatest among emergencymedical admissions and lowest among elective surgical patients.
The risk of critical illness did not vary by socioeconomic circumstances, but mortality was
higher among patients from deprived areas.
CONCLUSIONS AND RELEVANCE In this study, about 1 in 20 patients experienced a critical
illness resulting in ICU admission within 2 years of cancer diagnosis. The associated high
mortality rate maymake a significant contribution to overall cancer outcomes.
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better survival, such as France and Belgium, have 3 to 6
times the number of ICU beds per head of population than
the United Kingdom.3,7
About 1 in 7 ICUpatients has amalignant neoplasm, but it
isnotknown, atpresent,whether thepersistingeffectsof criti-
cal illness and ICU care interfere with planned cancer treat-
ment or contribute to overall survival.8 A recent systematic
review9 reported an average ICUmortality of 31% and hospi-
talmortality of 38%, althoughoutcomesvariedby cancer site,
type of admission (whether planned or emergency) and spe-
cialty. Development of a critical illness requiring ICU support
may be an important clinical event that contributes to poorer
overall survival. It would therefore be useful to understand
which patients with cancer are at greatest risk of critical ill-
ness as a basis for identifying how thismight be prevented or
detectedearlier. Toour knowledge, however, researchhasnot
been published that evaluates the risks of critical illness re-
quiring ICU admission among patients with cancer.
The aim of our study was to describe risks of critical ill-
ness resulting in ICUadmissionamongpatientswith solid can-
cers. We performed a population-based study using linked
cancer registry, hospitalization, ICU audit, and death records
to determine risks after a cancer diagnosis.
Methods
Data Source
In this retrospective observational study we identified pa-
tients resident in theWest of Scotland regionwho had a diag-
nosis of a malignant cancer on the Scottish Cancer Registry
between 2000 and 2009, and we investigated whether they
had been admitted to 1 of the 16 general ICUs located in the
region within 2 years after the date of cancer incidence.
We used linked data from 4 Scottish data sets: the Scot-
tishCancerRegistry,ScottishMorbidityRecord01 (SMR01),Na-
tionalRecordsofScotlanddeathrecords,andWardWatcher ICU
database.TheScottishCancerRegistry collects informationon
all new cases of cancer, including primary malignant neo-
plasms, carcinoma in situ, neoplasms of uncertain behavior,
andbenignbrainandspinal cord tumors.Cancerdiagnosesare
coded to the International Statistical Classification ofDiseases
andRelatedHealthProblems,TenthRevision (ICD-10). The reg-
istry is linkedby the InformationServicesDivision (ISD)ofNHS
National Services Scotland using probabilistic linkage proce-
dures to inpatientanddaycasedischargesummaries fromnon-
obstetric, nonpsychiatric specialties in general acuteNHShos-
pitals (SMR01),NationalRecordsofScotlanddeathrecords,and
to the Scottish Intensive Care Society Audit Group (SICSAG)
WardWatcher ICU audit database.
The SICSAG WardWatcher audit system is used in ICUs
throughout Scotland and collects data on patient demo-
graphic details, admitting specialty, admission diagnosis, the
patient’s prior location, comorbidities, and type of organ sup-
port. TheSICSAGepisodeswerematched toSMR01 staysusing
the dates of hospital and ICU admission and discharge. This
allowed identification of type of hospital admission, admit-
ting specialty, and discharge type.
Setting
TheWestofScotlandregionof theUnitedKingdomhasapopu-
lation of 2.4 million. It is predominantly urban, with most of
the population living in large towns or the city of Glasgow.
There were 16 general ICUs in the area during the study pe-
riod. Some functioned as a combined ICU/high-dependency
unit (HDU) for some or all of the period.
In the United Kingdom, ICU level care is provided to pa-
tientswithmultiorgan failure or single-organ respiratory fail-
ure needing advanced respiratory support . The nursing staff
topatient ratio is 1:1, andHDUcare is available topatientswith
single-organ failure or those requiring high-intensity obser-
vation. The nurse to patient ratio is approximately 1:2. Be-
yondprofessional guidelines, there arenoabsolute criteria for
admission to a critical care area. The final decision rests with
the admitting clinician. Generally, patientswhohave a termi-
nal illness, refuse admission, or have a do not resuscitate or-
der would not be admitted.
Study Population
We included patients if theywere 16 years or older, resided in
the West of Scotland, and had a diagnosis of a solid tumor
(ICD-10 codes C00-C80, ignoring nonmelanoma skin cancer
codeC44) in theScottishCancerRegistry fromJanuary1,2000,
throughDecember 31, 2009.We identified if patientswere ad-
mitted to a general ICU up to 2 years after the date of inci-
dence. If a patienthadmore than 1 ICUadmission,weused the
first ICUadmission.For simplicity,patientswhohadmore than
1 cancer were grouped separately. The incidence date of the
earliest diagnosed tumor was used in cases of multiple can-
cers. We excluded patients who had brain, other central ner-
vous system, and intracranial tumors (ICD-10 codes C71-C72,
D32-D33, D35.2-D35.4, D42-D43, D44.3-D44.5) because they
are more likely to be admitted to a specialized ICU. Patients
with hematological cancers (ICD-10 codes C81-C96, D45-
D47) were excluded because there was a series of important
changes inguidance for treatmentandsupportofpatientswith
hematological malignant neoplasms over the study period.10
This study was approved by the West of Scotland Re-
search and Ethics Committee. Approvals to use the datawere
obtained fromtheWestof ScotlandCritical CareResearchNet-
work, SICSAG, and the West of Scotland Cancer Surveillance
Unit.
At a Glance
• More than 6000 patients out of more than 118 500with cancer
(5%) had been admitted to an ICUwithin 2 years of incident
cancer between 2000 and 2009.
• The risk of admission was highest among patients with
gastrointestinal cancer and lowest in those with prostate cancer,
breast cancer, andmelanoma of skin.
• Mortality after admission was highest among emergencymedical
admissions and lowest among elective surgical admissions.
• Hospital mortality was often high among those with cancers with
otherwise good prognoses, such as breast and colorectal cancer.
• Critical illness maymake an important contribution to overall
cancer outcomes.
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Statistical Analysis
Age- andsex-specific cumulative countsofnumbersof ICUad-
missionsexpressedasapercentageof the incidentcancerpopu-
lation were calculated by time since diagnosis. We compared
thepercentage of patients admitted to ICUby cancer type.We
investigated ICU admission by hospital admission type di-
chotomizedas emergencyor elective, specialty at hospital ad-
mission dichotomized as medical or surgical, and by receipt
of organ support. Organ support was defined as invasiveme-
chanicalventilationviaendotracheal tubeor tracheostomy,use
of inotropic or vasopressor medication, or renal replacement
therapy of any modality. The Scottish Index of Multiple De-
privation (SIMD) was used as an area-level measure of socio-
economic status. The SIMD is the Scottish Government’s of-
ficial tool for identifying deprived places in Scotland.11 The
SIMD uses 7 domains (employment, income, heath, educa-
tion, access to services, crime, andhousing) to rank6505small
geographical areas of Scotland from1 (most deprived) to 6505
(least deprived). These were grouped into national quintiles
labeled 1 (most deprived) to 5 (least deprived).
Organ support data prior to 2005 were not complete. We
visited ICU sites to obtain these data, but a high proportion of
missingdata remained.Receiptof anyorgansupport couldnot
be fully ascertained for 15% of patients prior to 2005 mainly
because of incomplete renal support data. The number who
received organ support prior to 2005 was therefore underes-
timated; however, theproportionof patientswho received re-
nal support only was small (0.8% of patients admitted after
2004), and thus we do not feel that the missing organ sup-
port data would substantially bias our findings.
Five centerswere combined ICU/HDUunits, andwecould
not differentiate patients admitted to ICU from those admit-
ted to an HDU. We used receipt of organ support to differen-
tiate patients. TheAPACHE II severity of disease scorewas re-
corded for 70%ofpatients admitted to an ICU.12WardWatcher
recordeddeaths thatoccurred inan ICU.Patientswhodieddur-
ing thehospital stay inwhich the ICUadmissionoccurredwere
identified from the SMR01 discharge summary or Ward-
Watcher database. A total of 76 ICU stays (1.2%) among pa-
tientswith cancer couldnot bematched to an SMR01 stay.We
limited the analysis of mortality to the 6040 patients with
matched ICU and SMR01 records.
Statistical analyses were performed using Stata software
(version 13; StataCorp LP). Unless otherwise stated, we de-
scribedmedians with interquartile ranges (IQR) and percent-
ages with exact 95% CIs and used a conventional level of .05
to indicate statistical significance.Weused fixed- andmixed-
effects logistic regression to analyze trends in mortality with
calendar year and to investigate variation between ICU units.
Results
Between 2000 and 2009, 118 541 patients were diagnosed as
having a cancer and were eligible for inclusion in study. The
medianagewas69years (IQR,59-77years), and61 607 (52.0%)
were women. Those 60 years or older accounted for three-
quarters of patients (74.8%) (Table 1).
Admission to ICU
Within2yearsofdiagnosis, 6116patients (5.2%[95%CI, 5.0%-
5.3%]) experienced a critical illness resulting in admission to
ICU. Their median age was 68 years (IQR, 60-75 years), and
2542 (41.6%) were women. The APACHE II score was re-
corded for 4279 patients (70.0%) (median score, 17; IQR, 13-
22). Following cancer diagnosis, the cumulative incidence of
ICUadmission(Figure) increasedsharply to3.7%(95%CI,3.6%-
3.9%) by 100 days. By 200 days the cumulative incidence
continued to increase, butmore slowly, to4.5%(95%CI,4.4%-
4.6%).
Admission to an ICU occurred during an emergency hos-
pital stay for 43.0% of patients. Organ support was received
by 59.3%of admittedpatients, or 3.1% (95%CI, 3.0%-3.2%) of
all patients with cancer. Among patients who received organ
support, 18.9%hadbeenadmitted toamedical specialtyathos-
pital admission. The proportion admitted to a medical spe-
cialty was higher at younger ages than at older ages.
Admission to an ICU increasedwith increasing age, rising
from2.2% (95%CI, 1.5%-3.3%) at ages 16 to29years to amaxi-
mum of 6.3% (95% CI, 6.1%-6.6%) at ages 60 to 69 years and
Table 1. Incident Cancers by Age Group, Showing Percentage Admitted to ICUWithin 2 Years of Diagnosis,
PercentageWho Received Organ Support, and Hospital Admission Specialty, 2000 to 2009a
Total Patients With Cancer,
Age Group, y (No. of
Patients)
Patients
Admitted to ICU
Patients Admitted to ICU
Hospital Admission Specialty
of Patients Who Received
Organ Supportb
Emergency
Hospital
Admission
Received Organ
Support Medical Surgical
16-29 (1163) 26 (2.2) 10 (38.5) 17 (65.4) 4 (23.5) 13 (76.5)
30-39 (3128) 90 (2.9) 45 (50.0) 48 (53.3) 12 (25.0) 36 (75.0)
40-49 (7844) 371 (4.7) 158 (42.6) 206 (55.5) 48 (23.3) 156 (75.7)
50-59 (17 690) 985 (5.6) 384 (39.0) 618 (62.7) 117 (18.9) 494 (79.9)
60-69 (30 749) 1945 (6.3) 781 (40.2) 1151 (59.2) 216 (18.8) 921 (80.0)
70-79 (35 423) 1938 (5.5) 829 (42.8) 1159 (59.8) 210 (18.1) 936 (80.8)
80-89 (19 557) 712 (3.6) 382 (53.7) 397 (55.8) 71 (17.9) 322 (81.1)
>90 (2987) 49 (1.6) 40 (81.6) 28 (57.1) 7 (25.0) 21 (75.0)
All (118 541) 6116 (5.2) 2629 (43.0) 3624 (59.3) 685 (18.9) 2899 (80.0)
Abbreviation: ICU, intensive care unit.
a Data are given as number
(percentage).
b Percentages do not sum to 100%
because some ICU patients could
not bematched to a hospital
admission record.
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declinedthereafter.Theriskofcritical illnesswashigher inmen
than in women for all age groups (see eFigure 1 in the Supple-
ment). The age-specific pattern of admissions in which pa-
tients receivedorgan supportwas similar to theoverall pattern
of ICU admission, but proportions were lower at all ages.
There was a decline in proportions of patients with can-
cer diagnosed from2000 to2009whodeveloped a critical ill-
ness andwere admitted to an ICUwithin 2 years (eFigure 2 in
theSupplement). Thedeclinewasgreater amongpatientswho
did not receive organ support; there were smaller reductions
in ICU admissions for patients who required organ support.
The cumulative incidence of critical illness and ICU ad-
mission followingdiagnosisof specific solid cancers are shown
in Table 2. The most frequent cancers were lung, breast, and
colorectal malignant neoplasms. The risks were greatest for
small intestinal and colorectal cancers (17.2% [95%CI, 13.3%-
21.8%] and 16.5% [95% CI, 15.9%-17.1%], respectively) fol-
lowedby stomach (11.3% [95%CI, 10.3%-12.3%]) andheadand
neck cancers (12.8% [95%CI, 11.9%-13.8%]). Cancer stagewas
not recorded formost cancer sites butwas available for 77.7%
of colorectal cancers (12 071 of 15 535). Admission to an ICU
was higher among patients with Dukes stage B and C colorec-
tal cancer (22.9% [95% CI, 21.6%-24.3%] and 23.8% [95% CI,
22.4%-25.3%, respectively) compared with Dukes stage A or
D (15.8% [95% CI, 14.1%-17.6%] and 9.6% [95% CI, 8.6%-
10.7%]). Two-fifths (41.9%) of all ICU admissions among
patients with solid cancers occurred in those with colorectal
cancers, with those with head and neck and stomach can-
cers contributing 10.4% and 7.4%, respectively. Although
breast cancer had a high incidence, the risk of critical illness
was among the lowest for all malignant neoplasms, at 0.8%
(95% CI, 0.7%-1.0%).
The proportion of admissions to ICUs that occurred dur-
ing an emergency hospital admission varied from a low of
25.3% for kidney and head and neck cancers, to 78.2% and
85.1% of patients with cancers of the small intestine and un-
known primary, respectively.
Receipt of organ support variedby cancer type, froma low
of47.8%(95%CI,45.9%-49.8%)ofpatientswithcolorectal can-
cer to91.5%(95%CI,89.1%-93.6%)of thosewithheadandneck
cancer. Most patients with cancer (80.0%) who received or-
gan support were surgical patients, but there was substantial
variation by cancer type. Over 85% of those with colorectal,
headandneck, stomach, bladder, kidney, andesophageal can-
cer were admitted from surgical specialties. In contrast, over
40%of thosewithbreast, lung,melanoma,ovary, cervical, and
cancers of unknown origin were medical admissions.
Seventy percent of ICU patients were admitted within 3
monthsof thedateof cancer incidence (eTable 1 in theSupple-
ment). Notable exceptions include breast, bladder, prostate,
and testicular cancerwhen around 37%or lesswere admitted
within 3 months. Cancers with poorer survival, such as lung,
liver, and ovarianmalignant neoplasms, had the highest pro-
portions of ICU admissions within 3 months of incidence, at
75.6%,77.6%,and87.7%, respectively.Patientswhoweremedi-
cal admissions weremore likely to be admitted to ICUwithin
14 days of cancer incidence comparedwith patients admitted
to surgical specialties (38.6%comparedwith23.2%;P < .001).
Mortality
A total of 852 of 6040 patients with cancer (14.1% [95% CI,
13.2%-15.0%]) died during their stay in an ICU. Mortality
varied by type of hospital admission, specialty, and organ
support (Table 3). Mortality among patients who received or-
gan support was approximately 10 times that experienced by
patients who did not (22.2% [95% CI, 20.9%-23.6%] com-
paredwith2.3%[95%CI, 1.8%-3.0%]).Theproportionofdeaths
among the 685medical patients who received organ support
Figure. Cumulative Incidence of Admission to Intensive Care Units (ICUs) by Time Since Cancer Incidence Date
6
5
4
3
2
1
0
0 800600
Cu
m
ul
at
iv
e 
In
ci
de
nc
e 
of
 IC
U 
Ad
m
is
si
on
, %
Days Since Cancer Incidence
200 400
All ICU admissions
Received organ support
Shaded areas indicate 95% CIs.
Risk of Critical Illness Among Patients With Solid Cancers Original Investigation Research
jamaoncology.com (Reprinted) JAMAOncology November 2015 Volume 1, Number 8 1081
Downloaded From: http://oncology.jamanetwork.com/ by a GLASGOW UNIVERSITY LIBRARY User  on 11/27/2015
Copyright 2015 American Medical Association. All rights reserved.
(38.4% [95%CI, 34.7%-42.2%])was twice that experiencedby
the 2899 patients admitted from a surgical specialty (18.4%
[95%CI, 17.0%-19.8%]). The lowest ICUmortality of less than
1% (0.6% [95% CI, 0.3%-1.2%]) occurred among 1448 pa-
tients who were elective surgical admissions that did not re-
ceive organ support. In contrast, 41.7% (95% CI, 37.6%-
45.8%) of 576 patients who were emergency medical
admissions that had received organ support died in the ICU.
Atotalof 1486patients (24.6%[95%CI,23.5%-25.7%])died
during the hospital stay inwhich an ICU admission occurred;
just under half of these deaths (10.5%) happened after dis-
charge from ICU. The percentage of ICU patients who died in
hospital was higher among those who received organ sup-
port (34.8%[95%CI, 33.2%-36.4%]) comparedwith thosewho
hadnot (9.7%[95%CI,8.6%-11.0%]).Followingdischarge from
an ICU, hospital deaths among surgical patientswho received
Table 2. ICU AdmissionsWithin 2 Years of Cancer Incidence by Cancer Type, 2000 to 2009a
Type of Cancer
(No. of Patients)
All Patients With
Cancer Admitted
to ICU
Patients Admitted to ICU
Hospital’s Admission Specialty
of Patients Who Received Organ
Supportb
Emergency
Hospital
Admission
Received Organ
Support Medical Surgical
Colorectal (15 535) 2561 (16.5) 1167 (45.6) 1225 (47.8) 134 (10.9) 1074 (87.7)
Head and neck (4958) 636 (12.8) 164 (25.8) 582 (91.5) 47 (8.1) 533 (91.6)
Stomach (4045) 456 (11.3) 129 (28.3) 234 (51.3) 34 (14.5) 199 (85.0)
Esophagus (3815) 389 (10.2) 74 (19.0) 255 (65.6) 21 (8.2) 231 (90.6)
Lung (23 443) 381 (1.6) 230 (60.4) 285 (74.8) 138 (48.4) 145 (50.9)
Kidney (3054) 249 (8.2) 63 (25.3) 137 (55.0) 14 (10.2) 120 (87.6)
Bladder (3523) 182 (5.2) 68 (37.4) 115 (63.2) 13 (11.3) 101 (87.8)
Breast (17 591) 149 (0.8) 94 (63.1) 93 (62.4) 37 (39.8) 53 (57.0)
Ovary (2910) 138 (4.7) 84 (60.9) 68 (49.3) 42 (61.8) 26 (38.2)
Prostate (11 337) 136 (1.2) 71 (52.2) 85 (62.5) 25 (29.4) 58 (68.2)
Cervix and corpus uteri
(3721)
113 (3.0) 58 (51.3) 65 (57.5) 44 (67.7) 20 (30.8)
Unknown (5722) 121 (2.1) 103 (85.1) 88 (72.7) 43 (48.9) 45 (51.1)
Pancreas (2920) 81 (2.8) 61 (75.3) 56 (69.1) 10 (17.9) 45 (80.4)
Liver (2291) 67 (2.9) 43 (64.2) 50 (74.6) 19 (38.0) 31 (62.0)
Small intestine (319) 55 (17.2) 43 (78.2) 33 (60.0) 12 (36.4) 21 (63.6)
Thyroid (700) 28 (4.0) 11 (39.3) 18 (64.3) 5 (27.8) 13 (72.2)
Testis (1018) 26 (2.6) 14 (53.8) 21 (80.8) 7 (33.3) 14 (66.7)
Melanoma of skin (4070) 18 (0.4) 13 (72.2) 14 (77.8) 6 (42.9) 8 (57.1)
Mesothelioma (1029) 18 (1.7) 12 (66.7) 13 (72.2) 5 (38.5) 7 (53.8)
Other (3163) 106 (3.4) 53 (50.0) 59 (55.7) 18 (30.5) 40 (67.8)
Multiple (3377) 206 (6.1) 74 (35.9) 128 (62.1) 11 (8.6) 115 (89.8)
Total (118541) 6116 (5.2) 2629 (43.0) 3624 (59.3) 685 (18.9) 2899 (80.0)
Abbreviation: ICU, intensive care unit.
a Data are given as No. (%).
b Percentages do not sum to 100%
because some ICU patients could
not bematched to a hospital
admission record.
Table 3. ICU andHospital Mortality by Hospital Admission Type, Specialty, and Organ Supporta
Hospital Admission Specialty
Elective Admission Emergency Admission
No Organ Supportb Organ Support No Organ Supporta Organ Support
Patients Died in ICU
Medical admission
% (95% CI) 5.1 (1.4-12.5) 21.1 (13.9-30.0) 5.9 (3.0-10.4) 41.7 (37.6-45.8)
No./Total No. 4/79 23/109 11/185 240/576
Surgical admission
% (95% CI) 0.6 (0.3-1.2) 14.5 (12.9-16.3) 4.3 (3.0-6.0) 24.5 (22.0-27.1)
No./Total No. 9/1448 258/1775 32/744 275/1124
Patients Died in Hospital
Medical admission
% (95% CI) 12.7 (6.2-22.0) 40.4 (31.1-50.2) 32.4 (25.7-39.7) 60.1 (55.9-64.1)
No./Total No. 10/79 44/109 60/185 346/576
Surgical admission
% (95% CI) 4.1 (3.2-5.3) 22.2 (20.3-24.2) 14.7 (12.2-17.4) 41.2 (38.3-44.1)
No./Total No. 60/1448 394/1775 109/744 463/1124
Abbreviation: ICU, intensive care unit.
a Given as percentages of patients
who died (95% CI) with numbers of
patients.
b Includes patients with organ
support not known.
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organ support increased by 11.2% to 29.6% (95% CI, 27.9%-
31.3%) and amongmedical patients to 56.9% (95% CI, 53.1%-
60.7%) (an18.5%increase).Less than5%ofpatients (4.1%[95%
CI, 3.2%-5.3%])whowereelective surgical admissions thatdid
not receive organ support died during their hospital stay
(Table 4). In contrast, 60.1% (95% CI, 55.9%-64.1%) of pa-
tientswhowere emergencymedical admissions and received
organ support died in hospital.
Theproportionofdeathsduring thehospital stay (Table4)
was highest for patients with cancers of unknown primary
(72.5% [95% CI, 63.6%-80.3%]), lung cancer (60.3% [95% CI,
55.2%-65.3%]), and liver cancer (56.7% [95% CI, 44.0%-
68.8%]).Hospitalmortalitywas lowest for thosewithheadand
neck cancers (11.8% [95% CI, 9.4%-14.5%]), multiple cancers
(17.6% [95%CI, 12.7%-23.6%]), kidney cancer (14.3% [95%CI,
10.2%-19.3%]), and thyroid cancer (10.7% [95% CI, 2.3%-
28.2%]). For most cancers, ICU mortality was substantially
higher among patients who were admitted as an emergency
patient or had received organ support. Mortality was higher
still among thosepatientsadmitted tomedical specialties com-
pared with those admitted to surgical specialties. For ex-
ample,hospitalmortality formedicalandsurgicalpatientswith
lung cancer who were emergency admissions and had re-
ceived organ support was 75.4% (95% CI, 67.1%-82.5%) and
62.0% (95% CI, 47.2%-75.3%), respectively.
Therewasnoclear trend in theproportionsofpatientswith
cancer admitted to ICUwhenexaminedby socioeconomicde-
privation (eTable 2 in the Supplement). The proportion of pa-
tients who were emergency hospital admissions or who re-
ceivedorgan supportwashigher in themostdeprivedquintile
(46.6% [95% CI, 44.3%-48.9%] and 68.5% [95% CI, 66.3%-
70.6%], respectively) comparedwith the least deprivedquin-
tile (41.1% [95%CI, 37.4%-44.9%],P = .01; and58.2% [95%CI,
54.4%-61.9%], P < .001). Mortality among patients admitted
from themost deprived areaswas significantly higher (29.4%
[95%CI, 27.3%-31.6%]) than that among thosewho lived in the
least deprived areas (21.8% [95% CI, 18.7%-25.1%], P < .001).
There was significant variation in hospital mortality be-
tween units. This was not associated with the volume of
patients admitted to ICU (P = .76) after adjusting for sex, age,
organ support, admission type, admission specialty, SIMD,
and calendar year (eTable 3 in the Supplement). There was a
slight fall in overall hospital mortality over the study period
(eFigure3 in theSupplement), but thiswasnot statistically sig-
nificant (P = .19) (eTable 3 in the Supplement). The year-on-
year odds ratio for hospital mortality was 0.98 (95% CI, 0.95-
1.01).Therewas,however, significantvariation in the temporal
trend inmortality between ICUcenters (σtrend = 0.04 [95%CI,
0.02-0.09]).
Discussion
In the first study of its kind, we have shown that just over 5%
ofpatientswithcancerdevelopedacritical illness requiring ICU
admission within 2 years of cancer diagnosis. The risk in-
Table 4. Hospital Mortality by Cancer Sitea
Cancer Site (No. of Patients)
All Patients
(n = 6040)
Emergency
Admission
(n = 2629)
Received Organ
Support
(n = 3584)
Emergency Admissions, Received Organ Support
Total
(n = 1700)
Medical
(n = 576)
Surgical
(n = 1124)
Colorectal (2519) 20.1 (18.5-21.7) 27.8 (25.3-30.5) 35.0 (32.3-37.8) 40.7 (36.9-44.6) 52.6 (43.1-61.9) 38.2 (34.1-42.4)
Head and neck (634) 11.8 (9.4-14.6) 23.2 (16.9-30.4) 12.1 (9.5-15.0) 24.3 (17.4-32.2) 36.1 (20.8-53.8) 20.2 (13.0-29.2)
Stomach (454) 23.3 (19.5-27.5) 39.5 (31.0-48.5) 38.6 (32.3-45.2) 55.0 (43.5-66.2) 66.7 (48.2-82.0) 46.8 (32.1-61.9)
Lung (378) 60.3 (55.2-65.3) 67.8 (61.4-73.8) 68.6 (62.8-73.9) 71.7 (64.5-78.1) 75.4 (67.1-82.5) 62.0 (47.2-75.3)
Esophagus (386) 20.2 (16.3-24.6) 35.1 (24.4-47.1) 25.8 (20.5-31.7) 42.6 (29.2-56.8) 72.2 (46.5-90.3) 27.8 (14.2-45.2)
Kidney (245) 14.3 (10.2-19.3) 28.6 (17.9-41.3) 23.9 (16.9-32.0) 39.5 (25.0-55.6) 28.6 (8.4-58.1) 44.8 (26.4-64.3)
Bladder (181) 27.1 (20.7-34.2) 50.0 (37.6-62.4) 32.5 (24.0-41.9) 54.8 (38.7-70.2) 53.8 (25.1-80.8) 55.2 (35.7-73.6)
Breast (144) 29.9 (22.5-38.0) 42.6 (32.4-53.2) 43.3 (32.9-54.2) 53.7 (41.1-66.0) 61.1 (43.5-76.9) 45.2 (27.3-64.0)
Ovary (137) 29.2 (21.7-37.6) 33.3 (23.4-44.5) 41.2 (29.4-53.8) 46.5 (31.2-62.3) 57.1 (34.0-78.2) 36.4 (17.2-59.3)
Prostate (132) 27.3 (19.9-35.7) 43.7 (31.9-56.0) 37.3 (27.0-48.7) 50.0 (36.1-63.9) 63.6 (40.7-82.8) 40.6 (23.7-59.4)
Cervix and corpus uteri (112) 18.8 (12.0-27.2) 27.6 (16.7-40.9) 29.7 (18.9-42.4) 35.9 (21.2-52.8) 35.0 (15.4-59.2) 36.8 (16.3-61.6)
Unknown (120) 72.5 (63.6-80.3) 78.6 (69.5-86.1) 76.1 (65.9-84.6) 82.9 (72.5-90.6) 82.5 (67.2-92.7) 83.3 (67.2-93.6)
Pancreas (79) 46.8 (35.5-58.4) 47.5 (34.6-60.7) 54.5 (40.6-68.0) 56.8 (41.0-71.7) 50.0 (18.7-81.3) 58.8 (40.7-75.4)
Liver (67) 56.7 (44.0-68.8) 65.1 (49.1-79.0) 58.0 (43.2-71.8) 66.7 (47.2-82.7) 56.3 (29.9-80.2) 78.6 (49.2-95.3)
Small intestine (54) 29.6 (18.0-43.6) 27.9 (15.3-43.7) 42.4 (25.5-60.8) 38.5 (20.2-59.4) 44.4 (13.7-78.8) 35.3 (14.2-61.7)
Thyroid (28) 10.7 (2.3-28.2) 27.3 (6.0-61.0) 5.6 (0.1-27.3) 12.5 (0.3-52.7) 0 (0-60.2) 25.0 (0.6-80.6)
Testis (26) 42.3 (23.4-63.1) 71.4 (41.9-91.6) 47.6 (25.7-70.2) 75.0 (42.8-94.5) 100 (59.0-100) 40.0 (5.3-85.3)
Melanoma of skin (18) 27.8 (9.7-53.5) 30.8 (9.1-61.4) 35.7 (12.8-64.9) 36.4 (10.9-69.2) 33.3 (4.3-77.7) 40.0 (5.3-85.3)
Mesothelioma (17) 47.1 (23.0-72.2) 58.3 (27.7-84.8) 58.3 (27.7-84.8) 70.0 (34.8-93.3) 80.0 (28.4-99.5) 60.0 (14.7-94.7)
Other (105) 26.7 (18.5-36.2) 35.8 (23.1-50.2) 39.7 (27.0-53.4) 46.9 (29.1-65.3) 36.4 (10.9-69.2) 52.4 (29.8-74.3)
Multiple (204) 17.6 (12.7-23.6) 29.7 (19.7-41.5) 26.2 (18.8-34.8) 39.2 (25.8-53.9) 55.5 (21.2-86.3) 35.7 (21.6-52.0)
All (6040) 24.6 (23.5-25.7) 37.2 (35.3-39.1) 34.8 (33.2-36.4) 47.6 (45.2-50.0) 60.1 (55.9-64.1) 41.2 (38.3-44.1)
a Data are given as percentages (95% CIs) of patients who died during the hospital stay in which they were admitted to an intensive care unit.
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creasedwithageandwashigheramongmen.Therewasamod-
estdecline in the rateof ICUadmissionduring the studyperiod
withhigheremergencyadmissions,receiptoforgansupport,and
hospitalmortalityamongmoresocioeconomicallydeprivedpa-
tients.Two-fifthsof critical illness followingacancerdiagnosis
occurred amongpatientswith colorectal cancers, but risks fol-
lowingbreastcancerwereamongthelowestofallmalignantneo-
plasms.Mortalitywashigh,with25%ofallpatientswithcancer
whodevelopedacritical illnessdyingduring the samehospital
stay.Wedidnot finda reduction inoverallmortalityduring the
studyperiod.Critical illnessmaythereforeplayanimportantrole
indeterminingoverall canceroutcomesandmayhelptoexplain
variations in cancer survival.
Patients with cancer may develop critical illness for many
reasons, but somebroadpatterns canbedescribed.First, there
is agroupofpatients forwhomastay inan ICU isofferedaspart
of elective surgical treatment.13 Such patients may have been
assessed preoperatively as being at higher risk of complica-
tions from coexistingmorbidities and thereforewould benefit
fromtheenhancedperioperativemonitoringofferedbyan ICU/
HDUenvironment.Their outcomesmightbeexpected tobe fa-
vorable because they have been selected for potentially cura-
tive treatment, and our results are consistent with this
suggestion. Patients who are emergency admissions associ-
atedwith a cancer diagnosis have poorer outcomes than those
whoare elective admissions, andpatientswhoaremedical ad-
missionshavepooreroutcomes thanthosewhoaresurgical ad-
missions.Again, theseobservationspartly reflectagroupofsur-
gical patients forwhomthecritical illness is likely tohavebeen
related to aperioperative insult rather thananongoing inflam-
matoryprocess that oftenoccurswithmedical patients. This is
a consistent finding seen in ICU patients regardless of comor-
bidityand isoftenaccounted forwhenusing ICUmortalitypre-
dictionscores.12While adirect comparisoncannotbemadebe-
cause of differences in casemix, the observation thatmedical
admissions had highermortality than emergency and elective
surgery admissions, respectively, has been made by Soares et
al.14 However, we are not aware of any published studies that
explore the role of a critical illness as part of the overall deter-
minants of survival in a nonselective cancer population.
We found that amongemergency colorectal cancer admis-
sions, hospital mortality was 38.2% in those admitted post-
operatively compared with 52.6% for patients with a nonop-
erative diagnosis. Patientswith cancer admitted to ICUwith a
medical diagnosis comprise amixture of thosewho are expe-
riencing the adverse effects of treatment, such as sepsis or tu-
mor lysis syndrome,15 and those experiencing progression of
their cancer. Overall survival frombreast cancer has been im-
provingover several decades such that the 5-year relative sur-
vival rate is around 86% in Scotland.16,17 We identified a sub-
group of patients with breast cancer with much higher
mortality, although we cannot say whether this was due to
breast cancer itself or an incidental critical illness. There is in-
creasing concern about use of systemic anticancer therapy
within the last few weeks of patients’ lives, and more de-
tailed characterizationofwhichpatients are at greatest risk of
critical illness requiring ICU carewill provide further insights
into outcomes.18 Hospital mortality among those with non-
surgical lung cancer, at 75.4%, was considerably higher than
that reported by Slatore et al19 at 34% or by Soares et al20 at
39%, and further analysis to compare case mix variables in
these patients is needed to try to explain these differences.
A major strength of this study is that it is the first pub-
lished research, to our knowledge, to describe risks of critical
illness among patients with a comprehensive coverage of
solid cancers. We believe that this population is representa-
tive of the overall population of patients with solid tumors
who are admitted to an ICU with a critical illness in the
United Kingdom. The large sample size, long observation
period, and high quality of cancer registration and ICU data
are also strengths.21,22
Theprincipal limitationisthatwecouldnot identifypatients
whosecritical illnessesdidnot result inadmissiontoanICU.We
were further limited inourability todifferentiateHDUpatients
from ICU patients in combined units. Although we found sig-
nificantvariation inmortalitybetweencenters,webelieve that
thismay reflect differences in casemix.While information on
diagnoses isavailable throughperson-linkedhospitaldischarge
records, the level of clinical severity isnot included.Aprospec-
tive study isneeded inwhicha rangeofphysiological and func-
tionalmeasures is included todetermineoutcomesamongpa-
tientswithcancerwhosecritical illnessesdo, anddonot, result
in ICUadmission.Ourstudywascarriedout inoneregionof the
UnitedKingdom, and,whilewedonot believe that admission
policiesare likely tobesignificantlydifferent thanthose inother
parts of theUnitedKingdom, furtherwork to repeat ourmeth-
odology in other geographic areas is needed.
Conclusions
TheUnitedKingdomhasbothpoorercanceroutcomesandcon-
siderably lower provision of ICU beds thanmost other devel-
oped countries.3,7 From our current results we cannot say
whether greater provisionof ICUbedswould contribute to im-
provements incancersurvival intheUnitedKingdom.However,
itmight be hypothesized that if ICUs are effective in reducing
mortality followinga critical illness, increased surveillance for
earlysignsofcritical illnessandgreatercapacitytooffer ICUcare
topatientswith cancermightbebeneficial. Studies areneeded
inwhichoutcomesof similarpatientswithcancerwhoare, and
are not, admitted to ICU are compared.
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Invited Commentary
Critical Care Utilization for ThoseWith Cancer
HowMuch Is Enough?
Knox H. Todd, MD, MPH, FACEP
Intensive care units (ICUs) provide specialized care that can
be of high value to those with cancer who experience life-
threatening complications of thedisease or its treatment. The
cost of providing intensive care is high, and unless the soci-
etal resourcesdevotedtohealthcareare limitless,wemustcon-
tinuallydecidehowtobest allocate resources to thosewhoare
likely to benefit.
While at one time, the diagnosis of cancermeant to clini-
cians that ICU admissions were largely futile, research sug-
gests that, given appropriate patient selection, the benefits of
critical care can be similar for those with and without a can-
cer diagnosis.1 While intensive care can provide health ben-
efits, particularly to thosewith reversible forms of organ fail-
ure, ICUcare involves thepossibility, and indeedthe likelihood,
ofphysicalpainandemotional suffering.Theprovisionofhigh-
quality critical care requires consideration of both the likeli-
hoodsof suchbenefits andharms. Cross-national studies play
a particularly important role in providing evidence for ratio-
nal critical carepractice. Countiesdifferwidely inmany forms
ofhealth care expenditures, including those related to ICUbed
capacity. These capacity rates vary several-fold between the
United States andEurope.Abetter understandingof this vari-
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